Total Yapay Kalp
Özet
Total yapay kalp (TAH) tedavisi, son yıllarda önemli ilerlemeler göstermiş olup, kısa süreli destek sağlayan büyük hacimli cihazlardan, uzun dönem destinasyon tedavi seçeneği olabilecek daha kompleks sistemlere doğru evrilmiştir. Gelecek çalışmaları, mevcut sınırlamaların — boyut, dayanıklılık, enfeksiyon riski ve yaşam kalitesi — aşılmasına, ayrıca pediatrik ve kompleks komorbiditeli hasta gruplarında kullanımın genişletilmesine odaklanmaktadır. Yeni mühendislik tasarımları cihaz boyutunu ve ağırlığını azaltmayı hedeflemekte, bu sayede çocuklar ve adölesanlar dâhil daha küçük vücut yapısına sahip erişkin hastalarda implantasyonu mümkün kılmaktadır. Gelişmiş biyomalzemeler ve biyouyumlu yüzey kaplamaları tromboembolik komplikasyonları, hemolizi ve enfeksiyonu azaltmayı amaçlamakta, biyoprotez tabanlı materyallerin kullanımı ise cihazın uzun dönem dayanıklılığını ve fizyolojik entegrasyonunu artırabilecek potansiyele sahiptir.
Mevcut sistemlerin en önemli zorluklarından biri perkütan driveline enfeksiyonlarıdır. Bu sorunu azaltmak amacıyla transkütan enerji transfer sistemleri (TETS) geliştirilmektedir. Bu teknoloji, tam implant edilebilir cihazlara geçişte büyük bir adım olup enfeksiyon riskini azaltmakta ve mobiliteyi artırmaktadır. Ayrıca yeni nesil TAH’lar, sensör destekli akıllı kontrol üniteleri ile gerçek zamanlı hemodinamik adaptasyon sağlayarak doğal biventriküler fizyolojiyi daha etkin şekilde taklit edebilecektir. Yapay zekâ entegrasyonu, cihaz yönetiminde prediktif bakım, kişiselleştirilmiş pompa optimizasyonu ve olası cihaz arızası ya da hemodinamik bozulmaların erken tespitine olanak sağlayacaktır. Telemonitorizasyon sistemleri sayesinde sürekli ayaktan hasta takibi mümkün olacak, güvenlik artarken hastane yatışları ve sağlık maliyetleri azalacaktır.
TAH geliştirmede en kritik ihtiyaçlardan biri pediatrik hastalara yönelik cihazların yaygınlaştırılmasıdır. Küçük boyutlu ve büyüme potansiyeline uygun cihazların yanı sıra, psikososyal destek, eğitim ve erişkine geçiş sürecinin yönetimi bu hasta grubunda uzun dönem sonuçların iyileştirilmesinde temel rol oynayacaktır. Gelecekte TAH, kalp-böbrek kombinasyonları gibi çoklu organ destek stratejileriyle de bütünleşebilir. Ayrıca pulmoner hipertansiyon ve sağ ventrikül afterload yönetimini optimize edebilecek adaptif modüllerin entegrasyonu da gündemdedir.
Yeni nesil biyoprotez TAH ve rotary pompa tabanlı sistemler (örneğin BiVACOR) erken klinik çalışmalarda cesaret verici sonuçlar ortaya koymaktadır. INTERMACS, EUROMACS ve uluslararası TAH kayıtlarının genişlemesi, hasta seçimini optimize etmek, cihaz tasarımını geliştirmek ve düzenleyici onay süreçlerini hızlandırmak açısından kritik veriler sağlayacaktır. TAH tedavisinin geleceği, mühendislik inovasyonlarının kişiselleştirilmiş tıp ve multidisipliner bakım ile bütünleşmesine dayanmaktadır. Miniatürizasyon, enfeksiyonsuz enerji transferi, yapay zekâ destekli izlem ve pediatrik hasta grubuna genişleme, TAH’ın köprü tedavisinden uzun dönem destinasyon tedavisine dönüşmesini mümkün kılacaktır. Teknolojinin klinik deneyimle buluşmasıyla, gelecek nesil TAH platformlarının yalnızca sağkalımı uzatmakla kalmayıp, yaşam kalitesini de belirgin olarak artırması beklenmektedir.
Referanslar
Chronic Heart Failure in Adults: Diagnosis and Management. National Institute for Health and Care Excellence: Guidelines. London2018.
Metra M, Teerlink JR. Heart failure. Lancet. 2017;390(10106):1981-95.
Subramaniam AV, Weston SA, Killian JM, Schulte PJ, Roger VL, Redfield MM, et al. Development of Advanced Heart Failure: A Population-Based Study. Circ Heart Fail. 2022;15(5):e009218.
Arabia FA, Cantor RS, Koehl DA, Kasirajan V, Gregoric I, Moriguchi JD, et al. Interagency registry for mechanically assisted circulatory support report on the total artificial heart. J Heart Lung Transplant. 2018;37(11):1304-12.
Yang M. Introduction to artificial hearts. In: Yang M, editor. Artificial Hearts: Elsevier; 2020. p. 1–20.
Garascia A, Palazzini M, Tedeschi A, Sacco A, Oliva F, Gentile P. Advanced heart failure: from definitions to therapeutic options. Eur Heart J Suppl. 2023;25(Suppl C):C283-C91.
Velleca A, Shullo MA, Dhital K, Azeka E, Colvin M, DePasquale E, et al. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2023;42(5):e1-e141.
Copeland H, Knezevic I, Baran DA, Rao V, Pham M, Gustafsson F, et al. Donor heart selection: Evidence-based guidelines for providers. J Heart Lung Transplant. 2023;42(1):7-29.
Watt T, John R. Total Artificial Heart vs LVAD and BIVAD. Semin Thorac Cardiovasc Surg. 2025.
Martin AC, Cholley B. The total artificial heart: An existential transformation beyond technology. Eur J Heart Fail. 2025;27(4):628-9.
Mehra MR, Cleveland JC, Jr., Uriel N, Cowger JA, Hall S, Horstmanshof D, et al. Primary results of long-term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 left ventricular assist device implants. Eur J Heart Fail. 2021;23(8):1392-400.
Logstrup BB, Nemec P, Schoenrath F, Gummert J, Pya Y, Potapov E, et al. Heart failure etiology and risk of right heart failure in adult left ventricular assist device support: the European Registry for Patients with Mechanical Circulatory Support (EUROMACS). Scand Cardiovasc J. 2020;54(5):306-14.
Mehra MR, Naka Y, Uriel N, Goldstein DJ, Cleveland JC, Jr., Colombo PC, et al. A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure. N Engl J Med. 2017;376(5):440-50.
Kormos RL, Cowger J, Pagani FD, Teuteberg JJ, Goldstein DJ, Jacobs JP, et al. The Society of Thoracic Surgeons Intermacs Database Annual Report: Evolving Indications, Outcomes, and Scientific Partnerships. Ann Thorac Surg. 2019;107(2):341-53.
Saeed D, Feldman D, Banayosy AE, Birks E, Blume E, Cowger J, et al. The 2023 International Society for Heart and Lung Transplantation Guidelines for Mechanical Circulatory Support: A 10- Year Update. J Heart Lung Transplant. 2023;42(7):e1-e222.
Arabia FA. Cardiac replacement: total artificial heart. Ann Cardiothorac Surg. 2020;9(2):68.
Lee T, Torregrossa G. Total Artificial Heart. In: Vasan RS, Sawyer DB, editors. Encyclopedia of Cardiovascular Research and Medicine: Elsevier; 2018. p. 545–57.
McLean J. The discovery of heparin. Circulation. 1959;19(1):75-8.
Carrel A, Lindbergh CA. The Culture of Whole Organs. Science. 1935;81(2112):621-3.
Gibbon JH. Artificial maintenance of circulation during experimental occlusion of pulmonary artery. Archives of Surgery. 1937;34(6):1105–31.
Matskeplishvili S. Vladimir Petrovich Demikhov (1916-1998): A pioneer of transplantation ahead of his time, who lived out the end of his life as an unknown and in poor circumstances. Eur Heart J. 2017;38(46):3406-10.
Glyantsev SP, Tchantchaleishvili V, Bockeria LA. Demikhov's "Mechanical Heart": The Circumstances Surrounding Creation of the World's First Implantable Total Artificial Heart in 1937. ASAIO J. 2016;62(1):106-9.
Langer RM. Vladimir P. Demikhov, a pioneer of organ transplantation. Transplant Proc. 2011;43(4):1221-2.
Shoja MM, Tubbs RS, Ardalan MR, Loukas M, Phagava H, Cohen-Gadol AA. A testimony to the history of heart and lung transplantation: English translation of Demikhov's paper, "Transplantation of the Heart, Lungs and other Organs". Int J Cardiol. 2010;143(3):230-4.
Konstantinov IE. At the cutting edge of the impossible: a tribute to Vladimir P. Demikhov. Tex Heart Inst J. 2009;36(5):453-8.
Konstantinov IE. A mystery of Vladimir P. Demikhov: the 50th anniversary of the first intrathoracic transplantation. Ann Thorac Surg. 1998;65(4):1171-7.
Cooper DK. Vladimir Demikhov. Ann Thorac Surg. 1995;59(6):1628.
Shumacker HB, Jr. A surgeon to remember: notes about Vladimir Demikhov. Ann Thorac Surg. 1994;58(4):1196-8.
Dodrill FD, Hill E, Gerisch RA. Temporary mechanical substitute for the left ventricle in man. J Am Med Assoc. 1952;150(7):642-4.
Hill JD, John H, Gibbon J. Part I. The development of the first successful heart-lung machine. Ann Thorac Surg. 1982;34(3):337-41.
Barnard CN. The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town. S Afr Med J. 1967;41(48):1271-4.
Haller JD, Cerruti MM. Heart transplantion in man: compilation of cases. January 1, 1964 to October 23, 1968. Am J Cardiol. 1968;22(6):840-3.
Shumway NE, Angell WW, Wuerflein RD. Progress in transplantation of the heart. Transplantation. 1967;5(4):Suppl:900-3.
Shumway NE, Angell WW, Wuerflein RD. Recent advances in cardiac replacement. Surgery. 1967;62(4):794-6.
Cooley DA, Liotta D, Hallman GL, Bloodwell RD, Leachman RD, Milam JD. Orthotopic cardiac prosthesis for two-staged cardiac replacement. Am J Cardiol. 1969;24(5):723-30.
Cooley DA, Akutsu T, Norman JC, Serrato MA, Frazier OH. Total artificial heart in two-staged cardiac transplantation. Cardiovasc Dis. 1981;8(3):305-19.
DeVries WC, Anderson JL, Joyce LD, Anderson FL, Hammond EH, Jarvik RK, et al. Clinical use of the total artificial heart. N Engl J Med. 1984;310(5):273-8.
Altman LK. William Schroeder dies 620 days after receiving artificial heart. N Y Times Web. 1986:A1, A25.
Akalin H, Çorapçioglu T, Uçanok K. Ülkemizde ilk yapay kalp (Symbion J-7) uygulaması. Türkiye Klinikleri. 1989;9:294–6.
Copeland J, Langford S, Giampietro J, Arancio J, Arabia F. Total Artificial Heart Update. Surg Technol Int. 2021;39:243-8.
Copeland JG, Arabia FA, Smith RG, Sethi GK, Nolan PE, Banchy ME. Arizona experience with CardioWest Total Artificial Heart bridge to transplantation. Ann Thorac Surg. 1999;68(2):756-60.
Arabia FA, Copeland JG, Smith RG, Banchy M, Foy B, Kormos R, et al. CardioWest total artificial heart: a retrospective controlled study. Artif Organs. 1999;23(2):204-7.
Arabia FA, Copeland JG, Pavie A, Smith RG. Implantation technique for the CardioWest total artificial heart. Ann Thorac Surg. 1999;68(2):698-704.
Copeland JGI, Arabia FA, Banchy ME. The CardioWest total artificial heart bridge to transplantation: 1993 to 1996 national trial. Annals of Thoracic Surgery. 1998;66:1662–9.
Rame JE, Pagani FD, Kiernan MS, Oliveira GH, Birati EY, Atluri P, et al. Evolution of Late Right Heart Failure With Left Ventricular Assist Devices and Association With Outcomes. J Am Coll Cardiol. 2021;78(23):2294-308.
Rivas-Lasarte M, Kumar S, Derbala MH, Ferrall J, Cefalu M, Rashid SMI, et al. Prediction of right heart failure after left ventricular assist implantation: external validation of the EUROMACS right-sided heart failure risk score. Eur Heart J Acute Cardiovasc Care. 2021;10(7):723-32.
Richez U, De Castilla H, Guerin CL, Gendron N, Luraghi G, Grimme M, et al. Hemocompatibility and safety of the Carmat Total Artifical Heart hybrid membrane. Heliyon. 2019;5(12):e02914.
Netuka I, Pya Y, Bekbossynova M, Ivak P, Konarik M, Gustafsson F, et al. Initial bridge to transplant experience with a bioprosthetic autoregulated artificial heart. J Heart Lung Transplant. 2020;39(12):1491-3.
Küçükaksu D, Pektok E, Arat N, Yıldız Ö, Demirozu Z, Ece F, et al. Total artificial heart for bridge to cardiac transplantation: first patient at home in Turkey. Türk Göğüs Kalp Damar Cerrahisi Dergisi 2013;21(4):1032-8.
Buyukatalay ZC, Agha Oghali AMN, Kendirli T, Can OS, Ucar T, Akar AR, et al. First Reported Cochlear Implantation in a Child with Total Artificial Heart. Exp Clin Transplant. 2021;19(12):1352-5.
Fox CS, McKenna KL, Allaire PE, Mentzer RM, Jr., Throckmorton AL. Total Artificial Hearts-Past, Current, and Future. J Card Surg. 2015;30(11):856-64.
Cooley DA. Heart substitution: transplantation and total artificial heart. The Texas Heart Institute experience. Artif Organs. 1985;9(1):12-6.
Jarvik RK. The total artificial heart. Sci Am. 1981;244(1):74-80.
Pavie A, Leger P, Regan M. Clinical experience with a total artificial heart as a bridge for transplantation: The Pitié experience. Journal of Cardiac Surgery. 1995;10:552–8.
Razumov A, Burri M, Zittermann A, Radakovic D, Lauenroth V, Rojas SV, et al. Outcomes after SynCardia(R) temporary total artificial heart implantation: A 20-year single-center experience in 196 patients. Artif Organs. 2025;49(2):266-75.
Meyer DM, Nayak A, Wood KL, Blumer V, Schettle S, Salerno C, et al. The Society of Thoracic Surgeons Intermacs 2024 Annual Report: Focus on Outcomes in Younger Patients. Ann Thorac Surg. 2025;119(1):34-58.
Akay MH, Gregoric ID. SynCardia Total Artificial Heart Implant Procedures and Techniques. In: Gregoric ID, Myers TJ, Mihalj M, editors. Management of Acute and Chronic Severe Heart Failure. Cham: Springer; 2024. p. 225–39.
Goodwin ML, Mokadam NA. Total Artificial Heart Implantation: How I Teach It. Ann Thorac Surg. 2019;108(5):1271-6.
Kato TS, Farr M, Schulze PC, Maurer M, Shahzad K, Iwata S, et al. Usefulness of two-dimensional echocardiographic parameters of the left side of the heart to predict right ventricular failure after left ventricular assist device implantation. Am J Cardiol. 2012;109(2):246-51.
Fukamachi K, Horvath DJ, Massiello AL, Fumoto H, Horai T, Rao S, et al. An innovative, sensorless, pulsatile, continuous-flow total artificial heart: device design and initial in vitro study. J Heart Lung Transplant. 2010;29(1):13-20.
Peng DM, Davies RR, Simpson KE, Shugh SB, Morales DLS, Jacobs JP, et al. Seventh Annual Society of Thoracic Surgeons Pedimacs Report. Ann Thorac Surg. 2024;117(4):690-703.
Chung JS, Emerson D, Megna D, Arabia FA. Total artificial heart: surgical technique in the patient with normal cardiac anatomy. Ann Cardiothorac Surg. 2020;9(2):81-8.
Han L, Wang W. Total Artificial Heart. In: Yang M, editor. Artificial Hearts. Singapore: Springer; 2020. p. 95–109.
Disque AA, Meltzer J. Cardiac Tamponade in a Patient with a 50 mL SynCardia Total Artificial Heart. J Cardiothorac Vasc Anesth. 2015;29(6):e86-9.
Slepian MJ, Alemu Y, Girdhar G, Soares JS, Smith RG, Einav S, et al. The Syncardia() total artificial heart: in vivo, in vitro, and computational modeling studies. J Biomech. 2013;46(2):266-75.
Copeland JG. SynCardia Total Artificial Heart: update and future. Tex Heart Inst J. 2013;40(5):587-8.
Ferng AS, Oliva I, Jokerst C, Avery R, Connell AM, Tran PL, et al. Translation of First North American 50 and 70 cc Total Artificial Heart Virtual and Clinical Implantations: Utility of 3D Computed Tomography to Test Fit Devices. Artif Organs. 2017;41(8):727-34.
Beasley G, Vogel C, Thrush P. Successful Physical Rehabilitation After Placement of a SynCardia Total Artificial Heart. Artif Organs. 2019;43(3):318-9.
Zwischenberger JB, Cox CS, Jr. ECMO in the management of cardiac failure. ASAIO J. 1992;38(4):751-3.
Copeland J, Copeland H, Nolan P, Gustafson M, Slepian M, Smith R. Results with an anticoagulation protocol in 99 SynCardia total artificial heart recipients. ASAIO J. 2013;59(3):216-20.
Federman M, Dragomer D, Grant S, Reemtsen B, Biniwale R. Use of bivalirudin for anticoagulation during implantation of total artificial heart. J Extra Corpor Technol. 2014;46(2):170-2.
Copeland H, Copeland JG, Smith RG. Total artificial heart. In: Morgan JA, Naka Y, editors. Surgical Treatment for Advanced Heart Failure. New York: Springer; 2013. p. 161–77.
Stulak JM, Romans T, Cowger J, Romano MA, Haft JW, Aaronson KD, et al. Delayed sternal closure does not increase late infection risk in patients undergoing left ventricular assist device implantation. J Heart Lung Transplant. 2012;31(10):1115-9.
Shah KB, Mankad AK, Tang DG, Kasirajan V. The total artificial heart. In: Eisen H, editor. Heart Failure. London: Springer-Verlag; 2017. p. 691–771.
Jimeno-San Martin L, Goni-Viguria R, Bengoechea L, Fernandez E, Mendiluce N, Romero C, et al. Postoperative management and nursing care after implantation of a total artificial heart: Scoping review. Enferm Intensiva (Engl Ed). 2024;35(3):213-28.
Zimmerman H, Coehlo-Anderson R, Slepian M, al. e. Device malfunction of the CardioWest total artificial heart secondary to catheter entrapment of the tricuspid valve. ASAIO Journal. 2010;56:481–2.
Kusne S, Mooney M, Danziger-Isakov L, Kaan A, Lund LH, Lyster H, et al. An ISHLT consensus document for prevention and management strategies for mechanical circulatory support infection. J Heart Lung Transplant. 2017;36(10):1137-53.
Runyan C, Barone H, Huie N, Hajj J. A comparison of driveline infection: left ventricular assist device vs. total artificial heart. ASAIO 63rd Conference2017.
Shoham AB, Patel B, Arabia FA, Murray MJ. Mechanical ventilation and the total artificial heart: optimal ventilator trigger to avoid post-operative autocycling - a case series and literature review. J Cardiothorac Surg. 2010;5:39.
Shah KB. Renal function after implantation of the total artificial heart. Ann Cardiothorac Surg. 2020;9(2):124-5.
El-Banayosy A, Arusoglu L, Morshuis M, Kizner L, Tenderich G, Sarnowski P, et al. CardioWest total artificial heart: Bad Oeynhausen experience. Ann Thorac Surg. 2005;80(2):548-52.
Copeland JG, Smith RG, Arabia FA, Nolan PE, McClellan D, Tsau PH, et al. Total artificial heart bridge to transplantation: a 9-year experience with 62 patients. J Heart Lung Transplant. 2004;23(7):823-31.
Roussel JC, Senage T, Baron O, Perigaud C, Habash O, Rigal JC, et al. CardioWest (Jarvik) total artificial heart: a single-center experience with 42 patients. Ann Thorac Surg. 2009;87(1):124-9; discussion 30.
Smadja DM, Ivak P, Pya Y, Latremouille C, Gustafsson F, Roussel JC, et al. Intermediate-dose prophylactic anticoagulation with low molecular weight heparin is safe after bioprosthetic artificial heart implantation. J Heart Lung Transplant. 2022;41(9):1214-7.
Monteagudo-Vela M, Bowles C, Raj B, Robinson D, Simon A. Anticoagulation in syncardia total artificial heart recipients: anti-factor Xa or activated partial thromboplastin time? Interact Cardiovasc Thorac Surg. 2022;34(2):322-5.
Ramirez A, Riley JB, Joyce LD. Multi-Targeted Antithrombotic Therapy for Total Artificial Heart Device Patients. J Extra Corpor Technol. 2016;48(1):27-34.
Ensor CR, Cahoon WD, Crouch MA, Katlaps GJ, Hess ML, Cooke RH, et al. Antithrombotic therapy for the CardioWest temporary total artificial heart. Tex Heart Inst J. 2010;37(2):149-58.
Crouch MA, Kasirajan V, Cahoon W, Katlaps GJ, Gunnerson KJ. Successful use and dosing of bivalirudin after temporary total artificial heart implantation: a case series. Pharmacotherapy. 2008;28(11):1413-20.
Volod O, Arabia FA, Lam LD, Runge A, Cheng C, Czer LSC. Platelet Mapping by Thromboelastography and Whole Blood Aggregometry in Adult Patients Supported by Mechanical Circulatory Support Device on Aspirin Therapy. J Extra Corpor Technol. 2020;52(1):13-21.
Tan MC, Yeo YH, Tham JW, Tan JL, Fong HK, Tan BE, et al. Adverse Events in Total Artificial Heart for End-Stage Heart Failure: Insight From the Food and Drug Administration Manufacturer and User Facility Device Experience (MAUDE). Int J Heart Fail. 2024;6(2):76-81.
Mahfood Haddad T, Saurav A, Smer A, Azzouz MS, Akinapelli A, Williams MA, et al. Cardiac Rehabilitation in Patients With Left Ventricular Assist Device: A SYSTEMATIC REVIEW AND META-ANALYSIS. J Cardiopulm Rehabil Prev. 2017;37(6):390-6.
Hildebrandt A, Willemsen D, Reiss N, Bartsch P, Schmidt T, Bjarnason-Wehrens B. Characteristics, Therapeutic Needs, and Scope of Patients With a Continuous-Flow Left Ventricular Device Entering Cardiac Rehabilitation: A RETROSPECTIVE ANALYSIS. J Cardiopulm Rehabil Prev. 2019;39(2):91-6.
Kerrigan DJ, Cowger JA, Keteyian SJ. Exercise in patients with left ventricular devices: The interaction between the device and the patient. Prog Cardiovasc Dis. 2022;70:33-9.
Alswyan AH, Liberato ACS, Dougherty CM. A Systematic Review of Exercise Training in Patients With Cardiac Implantable Devices. J Cardiopulm Rehabil Prev. 2018;38(2):70-84.
Brown KD, Adams J, Meyer DM. Exercise training with cycle ergometry in the intensive care unit after total artificial heart implantation. Proc (Bayl Univ Med Cent). 2020;33(4):674-6.
Streur MM, Beckman JA, Dougherty CM, Li S, Mahr C. Quality of life and rehabilitation after total artificial heart. Ann Cardiothorac Surg. 2020;9(2):128-30.
Bellotto F, Compostella L, Agostoni P, Torregrossa G, Setzu T, Gambino A, et al. Peripheral adaptation mechanisms in physical training and cardiac rehabilitation: the case of a patient supported by a CardioWest total artificial heart. J Card Fail. 2011;17(8):670-5.
Hambrecht R, Gielen S, Linke A, Fiehn E, Yu J, Walther C, et al. Effects of exercise training on left ventricular function and peripheral resistance in patients with chronic heart failure: A randomized trial. JAMA. 2000;283(23):3095-101.
Dowling RD, Gray LA, Jr., Etoch SW, Laks H, Marelli D, Samuels L, et al. Initial experience with the AbioCor implantable replacement heart system. J Thorac Cardiovasc Surg. 2004;127(1):131-41.
Dowling RD, Etoch SW, Stevens KA, Johnson AC, Gray LA, Jr. Current status of the AbioCor implantable replacement heart. Ann Thorac Surg. 2001;71(3 Suppl):S147-9; discussion S83-4.
Copeland JG, Smith RG, Arabia FA, Nolan PE, Sethi GK, Tsau PH, et al. Cardiac replacement with a total artificial heart as a bridge to transplantation. N Engl J Med. 2004;351(9):859-67.
Leprince P, Bonnet N, Rama A, Leger P, Bors V, Levasseur JP, et al. Bridge to transplantation with the Jarvik-7 (CardioWest) total artificial heart: a single-center 15-year experience. J Heart Lung Transplant. 2003;22(12):1296-303.
Leprince P, Bonnet N, Varnous S, Rama A, Leger P, Ouattara A, et al. Patients with a body surface area less than 1.7 m2 have a good outcome with the CardioWest Total Artificial Heart. J Heart Lung Transplant. 2005;24(10):1501-5.
Kohli HS, Canada J, Arena R, Tang DG, Peberdy MA, Harton S, et al. Exercise blood pressure response during assisted circulatory support: comparison of the total artificial [corrected] heart with a left ventricular assist device during rehabilitation. J Heart Lung Transplant. 2011;30(11):1207-13.
Malas J, Chen Q, Akhmerov A, Tremblay LP, Egorova N, Krishnan A, et al. Experience With SynCardia Total Artificial Heart as a Bridge to Transplantation in 100 Patients. Ann Thorac Surg. 2023;115(3):725-32.
Carpentier A, Latremouille C, Cholley B, Smadja DM, Roussel JC, Boissier E, et al. First clinical use of a bioprosthetic total artificial heart: report of two cases. Lancet. 2015;386(10003):1556-63.
Pya Y, Jansen P. Management of Patients Supported by the Aeson Bioprosthetic Total Artificial Heart. In: Gregoric ID, Myers TJ, Mihalj M, editors. Management of Acute and Chronic Severe Heart Failure. Cham: Springer; 2024. p. 257–67.
Pya Y, Bekbossynova M, Medressova A, Latremouille C, Jansen P, Tauyekelova A, et al. Precise monitoring of transpulmonic resistance in bridge-to-transplant patients supported by the Aeson total artificial heart. J Heart Lung Transplant. 2025;44(7):1161-4.
Netuka I, Pya Y, Poitier B, Ivak P, Konarik M, Perles JC, et al. First Clinical Experience With the Pressure Sensor-Based Autoregulation of Blood Flow in an Artificial Heart. ASAIO J. 2021;67(10):1100-8.
Smadja DM, Roux de Bezieux J, Peronino C, Jilet L, Ivak P, Pya Y, et al. Understanding Platelet Activation in the Aeson Bioprosthetic Total Artificial Heart: Insights From Aspirin Treatment and Outcomes. ASAIO J. 2025;71(9):701-10.
Han JJ. Aeson-The Carmat total artificial heart is approved for enrollment in the United States. Artif Organs. 2021;45(5):445-6.
Vincentelli A, Pya Y, Netuka I, Haneya A, Schmitto J, Kindo M, et al. Implantation Technique for the Aeson Total Artificial Heart. Operative Techniques in Thoracic and Cardiovascular Surgery. 2024;29(2):149–67.
CARMAT. CARMAT receives MDR CE marking for its Aeson® artificial heart (Class III, BTT) — Press release (28 Jul 2025) Vélizy-Villacoublay (FR): CARMAT; 2025 [Available from: https://www.carmatsa.com/en/press-release/carmat-receives-mdr-ce-marking-for-its-aeson-artificial-heart/.
Huenges K, Panholzer B, Cremer J, Haneya A. Case report-CARMAT: the first experience with the Aeson bioprosthetic total artificial heart as a bridge to transplantation in a case of post-infarction ventricular septal rupture. Front Cardiovasc Med. 2023;10:1211365.
Martin AC, Moussa MD, Panholzer B, Verde A, Guihaire J, Aubin H, et al. Initial Experience With Aeson Total Artificial Heart in Cardiogenic Shock Patients on Extracorporeal Life Support. JACC Heart Fail. 2025;13(6):1030-3.
Poitier B, Chocron R, Peronino C, Philippe A, Pya Y, Rivet N, et al. Bioprosthetic Total Artificial Heart in Autoregulated Mode Is Biologically Hemocompatible: Insights for Multimers of von Willebrand Factor. Arterioscler Thromb Vasc Biol. 2022;42(4):470-80.
Peronino C, Guerin CL, Ivak P, Guyonnet L, Chocron R, Detriche G, et al. Bioprosthetic Total Artificial Heart Implantation Does Not Induce Chronic Inflammation. ASAIO J. 2022;68(11):e173-e8.
Smadja DM, Saubamea B, Susen S, Kindo M, Bruneval P, Van Belle E, et al. Bioprosthetic Total Artificial Heart Induces a Profile of Acquired Hemocompatibility With Membranes Recellularization. J Am Coll Cardiol. 2017;70(3):404-6.
Pinney SP, Anyanwu AC, Lala A, Teuteberg JJ, Uriel N, Mehra MR. Left Ventricular Assist Devices for Lifelong Support. J Am Coll Cardiol. 2017;69(23):2845-61.
Weber BN, Kobashigawa JA, Givertz MM. Evolving Areas in Heart Transplantation. JACC Heart Fail. 2017;5(12):869-78.
Kleinheyer M, Timms DL, Greatrex NA, Masuzawa T, Frazier OH, Cohn WE. Pulsatile operation of the BiVACOR TAH - Motor design, control and hemodynamics. Annu Int Conf IEEE Eng Med Biol Soc. 2014;2014:5659-62.
Timms D, Fraser J, Thompson B, al. e. In-vitro and in-vivo testing of the BiVACOR rotary BiVAD/TAH. In: Dössel O, Schlegel W, editors. World Congress on Medical Physics and Biomedical Engineering. Munich, Germany: Springer; 2009. p. 624–6.
Fukamachi K, Shiose A, Massiello AL, Horvath DJ, Golding LA, Lee S, et al. Implantable continuous-flow right ventricular assist device: lessons learned in the development of a cleveland clinic device. Ann Thorac Surg. 2012;93(5):1746-52.
Fukamachi K, Karimov JH, Sunagawa G, Horvath DJ, Byram N, Kuban BD, et al. Generating pulsatility by pump speed modulation with continuous-flow total artificial heart in awake calves. J Artif Organs. 2017;20(4):381-5.
Fumoto H, Horvath DJ, Rao S, Massiello AL, Horai T, Takaseya T, et al. In vivo acute performance of the Cleveland Clinic self-regulating, continuous-flow total artificial heart. J Heart Lung Transplant. 2010;29(1):21-6.
Horvath D, Karimov JH, Byram N, Kuban B, Golding LA, Moazami N, et al. Sensorless Suction Recognition in the Self-Regulating Cleveland Clinic Continuous-Flow Total Artificial Heart. ASAIO J. 2015;61(6):726-8.
Horvath D, Byram N, Karimov JH, Kuban B, Sunagawa G, Golding LAR, et al. Mechanism of Self-Regulation and In Vivo Performance of the Cleveland Clinic Continuous-Flow Total Artificial Heart. Artif Organs. 2017;41(5):411-7.
Grzyb C, Du D, Nair N. Artificial Intelligence Approaches for Predicting the Risks of Durable Mechanical Circulatory Support Therapy and Cardiac Transplantation. J Clin Med. 2024;13(7).
Ali SM, Ali ZJ, Abd MM. Design and Modeling of a Soft Artificial Heart by Using the SolidWorks and ANSYS. IOP Conference Series: Materials Science and Engineering2020.
Elmzughi MF, Mohammed AH, Tawfeeq OA. Design and performance simulation of a soft artificial heart by using the ANSYS software. i‑manager’s Journal on Future Engineering and Technology. 2024.
Manjunath LH, Karthick V. Design and Analysis of Artificial Heart Model by Using Finite Element Analysis. Journal of Mines, Metals and Fuels (J Mines Met Fuels). 2022;70(10A):13–20.
Ali SM, Mahmood SS. Design of a New Generation Low‑Cost Advanced Soft Nano‑Artificial Heart for Permanent Use. 2024.
Itagaki S, Toyoda N, Egorova N, Sun E, Lee T, Boateng P, et al. Total artificial heart implantation as a bridge to transplantation in the United States. J Thorac Cardiovasc Surg. 2024;167(1):205-14 e5.
Arabia FA, Murray CF. The total artificial heart: where have we been, where are we now, where are we going? Indian J Thorac Cardiovasc Surg. 2023;39(Suppl 1):198-205.
